Joel W. Slaton

7.6k citations
118 papers · 6.0k indexed · h-index 42
Topics
Bladder and Urothelial Cancer Treatments (32 papers)Renal cell carcinoma treatment (16 papers)Angiogenesis and VEGF in Cancer (12 papers)

In The Last Decade

Joel W. Slaton

114 papers receiving 5.8k citations

Peers

Joel W. Slaton
Comparison fields: 5 of 137
  • Molecular Biology 2.5k
  • Surgery 1.9k
  • Pulmonary and Respiratory Medicine 1.6k
  • Oncology 1.6k
  • Cancer Research 933
Replace Yoshiyuki Kakehi with:
Yoshiyuki Kakehi Japan
Masaru Murai Japan
Sten Nilsson Sweden
Louis Lacombe Canada
Toshiyuki Kamoto Japan
J. Edson Pontes United States
Sam S. Chang United States
Ganesh S. Palapattu United States
Kevin M. Slawin United States
Cheol Kwak South Korea
Joel W. Slaton relative to Yoshiyuki Kakehi Japan Yoshiyuki Kakehi's profile →
Citations per field
00.5×1.5×
Yoshiyuki Kakehi · 1×
Citations per year

Countries citing papers authored by Joel W. Slaton

Since Specialization
Citations

This map shows the geographic impact of Joel W. Slaton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel W. Slaton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel W. Slaton more than expected).

Fields of papers citing papers by Joel W. Slaton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel W. Slaton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel W. Slaton. The network helps show where Joel W. Slaton may publish in the future.

Co-authorship network of co-authors of Joel W. Slaton

This figure shows the co-authorship network connecting the top 25 collaborators of Joel W. Slaton. A scholar is included among the top collaborators of Joel W. Slaton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel W. Slaton. Joel W. Slaton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 8
2 43
3 151
4 16
5 33
6 32
7 28
8 302
9 33
10 18
11 29
12 95
13 82
14 38
15
Inhibition of angiogenesis by interferon-alpha in human transitional cell carcinoma growing orthotopically in nude mice and study of combination therapy with cytoreductive chemotherapy
1
16
Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
50
17 40
18 41
19 22
20 21

About Joel W. Slaton

Joel W. Slaton is a scholar working on Urology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 118 papers that have together received 6.0k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (32 papers), Renal cell carcinoma treatment (16 papers) and Angiogenesis and VEGF in Cancer (12 papers). The work is most often cited by research in Urology (656 citations), Cancer Research (933 citations) and Oncology (1.6k citations). Joel W. Slaton has collaborated with scholars based in United States, Japan and Australia. Frequent co-authors include Colin P. Dinney, Gretchen M. Unger, Khalil Ahmed, Keiji Inoue, David A. Swanson, Curtis A. Pettaway, Paul Perrotte, David A. Levy, Guixia Wang and Kashif Ahmad. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and Analytical Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026